CVS Health Corp Q2 2025 Earnings Call Transcript

The following is excerpted from the question-and-answer section of the transcript.

Question: Lisa Gill - JPMorgan Chase & Co - Analyst : Congratulations on the results. And welcome, Brian. I look forward to meeting you. Obviously, Q2 strong performance and HCB up 40%, $600 million beat on the core side by our numbers. Underlying assumptions and visibility, when we think about how that looks post the quarter and the guidance that you've given, there's a lot of moving parts here. Can you maybe just talk about the level of visibility you have with some of the underlying assumptions are, your level of conviction moving into the back half of the year?

Question: Justin Lake - Wolfe Research LLC - Analyst : Wanted to get your early view on 2026 headwinds and tailwinds. Specifically, your thoughts on expectations for continued improvement in MA margins post you're putting in your 2026 bids, your thoughts on the sustainability of outperformance and share gains in the pharmacy business

Question: Stephen Baxter - Wells Fargo Securities LLC - Analyst : Just wanted to check in on the group MA margins. I was wondering where this PDR places margins for the business in 2025. And then appreciating the commentary on repricing. Just can you remind us when you're repricing Group MA, are you expecting to get all the way back to target margins for that 50% cohort in a single cycle? Or does it take longer than that given the magnitude of dislocation?

Question: George Hill - Deutsche Bank AG - Analyst : Can you hear me now? I apologize. New to the format here. And Brian, welcome to the call. Well, my question was about the outlook for -- good to have you. My outlook was about the pharmacy segment outlook for the back half of the year. Maybe could you break out if there's any changes in the vaccine outlook, talk about the impact of reimbursement stabilization and maybe the impact of the Rite Aid file buys? And are there any other moving pieces we should consider? And should we think about this performance is sustainable?

Question: Elizabeth Anderson - Evercore Inc - Analyst : Maybe following up on that a little bit. As we think about what you said in terms of moving CostVantage into the government business next year and maybe there's potentially some 340B impact. How do I think about the reimbursement landscape like as it stands now for 2026? Do you think you can as generally flat reimbursement, like all else equal or other puts or takes to think about as we're at this point, which obviously is still on the early side?

Question: Andrew Mok - Barclays Services Corp - Analyst : Can you help reconcile your favorable Medicare results in the HCB segment with the unfavorable results you're seeing at Oak Street. Is the pressure coming more from internal or external MA members? And are there any benefits or cost categories you would call out as driving the elevated pressure in Oak Street?

Question: Eric Percher - Nephron Research LLC - Analyst : I'll stick with Health Services. And Brian, a similar visibility question as you addressed on HCB earlier. It's proven harder to draw a line in the sand on delivery HBR. Can you speak to visibility at this point of the year? And maybe how much of the $200 million headwind was first half versus expectation for any improvement in the second half? And then for the team, I know there's no change in pharmacy services, but could you speak to the customer price improvements? And are you seeing more cost to retain this high 90s retention level?

Question: Erin Wright - Morgan Stanley - Analyst : I'm curious that your thoughts on the Part D space and how that's playing out relative to plan, how you think about the demo and the CMS announcement more recently on that front and how you're thinking about that into next year and maybe we don't have enough visibility yet on that, but I want to see how that's playing out in terms of behaviors in terms of utilization trends and what you're seeing across Pard D?

Question: John Ransom - Raymond James - Analyst : I'm proud of myself for this -- undertaking this new process. My question is -- and I know this is a small part of the business, but the front-end part of the drug retail business has been a struggle for the industry for probably as long as I've been covering it, which is forever. I just wonder as you look through your business strategies. What are we doing differently? And I'm intrigued that you're back in the business of even buying drugstores. But what's the long-term strategy to address the competitive pressures and the competitive position of the front end?